We believe better cancer therapies are needed to transform people’s lives. We are developing accessible off-the-shelf cancer RNA immunotherapies that will deliver durable benefits.

We are a global leader in exploiting a novel class of untapped, aberrantly expressed tumour-specific antigens (aeTSAs) or CryptigenTM TSAs that are shared across multiple patients with the same tumor type, for the development of off-the-shelf cancer vaccines across the landscape of difficult to treat cancers.

Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.

Our proprietary CryptoMapTM platform, created and optimized by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer, at the Université de Montréal, identifies shared, aberrantly expressed tumour-specific antigens (aeTSAs), known as CryptigenTM TSAs, that are hidden in ‘junk DNA’.

Better cancer therapies are needed to transform patient responses and their lives. We are developing accessible off-the-shelf cancer RNA immunotherapies that we believe will deliver more durable benefits to patients.

In 2022, we closed a $14M USD seed round from a transatlantic syndicate of top-tier international life sciences investors.

The company has backing from life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, the Harrington Discovery Institute and Novateur Ventures.

In addition to its top-tier international investor syndicate, Epitopea is also proud to be supported by a strong network of contract partners from the public and private sector, that are providing Epitopea with R&D related support.